HEARST, A MARKET LEADER IN HEALTHCARE TECHNOLOGY, ANNOUNCED AN EQUITY INVESTMENT IN M2GEN, A HEALTH INFORMATICS SUBSIDIARY OF MOFFITT CANCER CENTER.
The partnership will help accelerate the discovery of innovative cancer therapies and improve care for patients nationwide. The collaboration will provide funding to expand the efforts of the nation’s first major data sharing network among leading cancer institutions.
THE PREVIOUS ISSUE OF MOMENTUM MAGAZINE INCLUDED A FEATURE ON CAR T, AN EXPERIMENTAL IMMUNOTHERAPY THAT ENGINEERS A PATIENT’S OWN IMMUNE CELLS TO TARGET AND FIGHT CANCER.
On Oct. 18, 2017, the U.S. FDA announced approval of Yescarta, Kite Pharma’s Chimeric Antigen Receptor (CAR) T-cell Therapy for adults with diffuse large B-cell lymphoma. Moffitt Cancer Center has been critical to the advancement of this new, life-saving therapy. Dr. Frederick Locke, vice chair of Moffitt’s Department of Blood and Marrow Transplant and Cellular Immunotherapy, was the co-principal investigator of the national multi-center trial that led to the approval of Yescarta. Moffitt is proud to be leading the way in the development of new immunotherapies like CAR T.
MOFFITT RESEARCHERS WERE AMONG THOSE FROM 18 COUNTRIES AND 105 STUDY SITES WHO FOUND THE NEWEST HPV [HUMAN PAPILLOMAVIRUS] VACCINE IS HIGHLY EFFECTIVE AT PREVENTING HPV INFECTION AND DISEASE.
The study results, published in The Lancet, showed the 9vHPV vaccine (known as Gardasil 9) has long-term activity against HPV infection and disease. The study results support comprehensive vaccination programs and inform public health decision related to implementation, said Anna R. Giuliano, PhD, director of Moffitt’s Center for Infection Research in Cancer, and one of the world’s leading HPV experts.
WHEN YOU DONATE TO CANCER RESEARCH
Your gift will go directly to helping researchers and scientists develop the medicines and protocols that will advance cancer treatments and help cure patients. Simply put, your generosity will help save lives. Every gift, no matter the size, makes a difference. Now is the time to get involved and help make a difference.
